12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Cx621: Phase I start

This month, TiGenix will begin a Spanish Phase I trial to evaluate 2 doses of Cx621 given intralymphatically...

Read the full 67 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >